Navigation Links
Masimo to Present at the Thomas Weisel Partners Healthcare Conference 2009
Date:8/31/2009

IRVINE, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Masimo Corporation (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced that its management is scheduled to present at the Thomas Weisel Partners Healthcare Conference 2009 at the Four Seasons Hotel in Boston, Massachusetts, on Thursday, September 10, 2009, at 10:20 a.m. EDT. A live audiocast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the audiocast will be available following the live presentation.

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET(R) provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry((TM)), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO((R))), methemoglobin (SpMet((R))), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found athttp://www.masimo.com.

    Masimo Corporation
    Investor Contact:                                Media Contact:
    Mark P. de Raad                                  Dana Banks
    Executive Vice President and Chief               Manager,
    Financial Officer                                Public Relations
    Masimo Corporation                               Masimo Corporation
    (949) 297-7080                                   (949) 297-7348
    mderaad@masimo.com                               dbanks@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.


'/>"/>
SOURCE Masimo Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
2. Masimo Reports Second Quarter 2007 Financial Results
3. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
4. Masimo to Report Third Quarter 2007 Financial Results on October 30, 2007
5. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
6. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
7. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group
8. Masimo Announces Continuous Noninvasive Total Hemoglobin
9. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
10. Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference
11. Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/25/2017)... ... February 25, 2017 , ... ... Clinical Trials in an ongoing effort to create meaningful change by increasing ... pharmaceutical research with emphasis on consumers and patients’ mental health well-being. , Both ...
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company ... National Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month ... technology and is expected to deliver therapeutic levels of olanzapine for a period of ...
(Date:2/24/2017)... Tenn. , Feb. 24, 2017 ... ("Provectus" or the "Company"), a clinical-stage oncology and ... regarding the deadline to participate in its previously ... units, consisting of shares of common stock and ... and holders of listed warrants. ...
(Date:2/24/2017)... Symic Bio, a biopharmaceutical company focused on ... therapeutics, announced today the completion of enrollment for the ... The trial will evaluate the safety and efficacy of ... of restenosis following angioplasty. "We,re pleased ... said Nathan Bachtell , M.D., Chief Medical Officer ...
Breaking Biology Technology:
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
(Date:2/2/2017)... 2, 2017  EyeLock LLC, a market leader of ... paper " What You Should Know About Biometrics in ... user authenticity is a growing concern. In traditional schemes, ... However, traditional authentication schemes such as username/password suffer from ... authentication offers an elegant solution to the problem of ...
Breaking Biology News(10 mins):